POLB announces that, further to its announcement in March 2022, the construction of the computational artificial intelligence (AI) influenza disease model has been completed by CytoReason Limited, indicating that it is on track to deliver outputs in Q2 2023. The model aims to unlock clinically meaningful insights into influenza infection and recovery through the analysis of POLB’s unique human challenge trial data. We view this rapid progress on the collaboration as positive and envisage that fu ....
29 Nov 2022
Further AI collaboration progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Further AI collaboration progress
Poolbeg Pharma PLC (POLB:LON) | 10.6 0 2.4% | Mkt Cap: 53.0m
- Published:
29 Nov 2022 -
Author:
Karl Keegan -
Pages:
3
POLB announces that, further to its announcement in March 2022, the construction of the computational artificial intelligence (AI) influenza disease model has been completed by CytoReason Limited, indicating that it is on track to deliver outputs in Q2 2023. The model aims to unlock clinically meaningful insights into influenza infection and recovery through the analysis of POLB’s unique human challenge trial data. We view this rapid progress on the collaboration as positive and envisage that fu ....